Rapid Dose Therapeutics Announces Cease Trade Order Due to Delay in Annual Filings Under COVID-19 Duress

Ontario, Aug. 20, 2020 – Rapid Dose Therapeutics Corp. (CSE: DOSE) announces that, due to circumstances beyond its control created by and relating to the COVID-19 pandemic, the Company was not able to file its audited financial statements and management discussion and analysis for the year ended February 29, 2020 together with officers’ certificates relating theretoContinue reading “Rapid Dose Therapeutics Announces Cease Trade Order Due to Delay in Annual Filings Under COVID-19 Duress”

Rapid Dose Therapeutics and McMaster University Initiate QuickStrip™ COVID-19 Vaccine Research With Immediate Impact

— Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian Life Sciences company focused on innovative drug and active ingredient delivery solutions, is pleased to announce it has begun COVID-19 vaccine research in conjunction with McMaster University and the team lead by Drs. Alex Adronov, James Mahony, and Mark Larché. The federally-funded project tests the useContinue reading “Rapid Dose Therapeutics and McMaster University Initiate QuickStrip™ COVID-19 Vaccine Research With Immediate Impact”

Rapid Dose Therapeutics Files a Patent to Synthesize THC From CBD Using a Selective Delta 8 or Delta 9 Conversion Process

— Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian Life Sciences company focused on innovative drug and active ingredient delivery solutions, is pleased to announce it has filed a non-provisional patent with the USPTO for an “Apparatus for and method of converting cbd and/or cbd derivatives to at least one other type of cannabinoid and/orContinue reading “Rapid Dose Therapeutics Files a Patent to Synthesize THC From CBD Using a Selective Delta 8 or Delta 9 Conversion Process”